###begin article-title 0
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
Coding variant Met72Thr in the PEDF gene and risk of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 1261 1265 1261 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 675 678 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 760 763 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 876 879 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 1175 1178 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 1352 1355 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Using a candidate-gene approach, a recent case-control study identified a previously unknown association between neovascular age-related macular degeneration (AMD) and the coding Met72Thr variant in the pigment epithelium-derived factor (PEDF) gene in a Taiwan Chinese population. However, a subsequent replication study failed to see this association in a white European population. We noted an important difference in the sample ascertainment scheme between these two studies. The original study did not consider findings of indocyanine green (ICG) angiography for disease classification, which is the only way to obtain a clear image of polypoidal choroidal vasculopathy (PCV) lesions. This suggests that their cohort might include a considerable amount of PCV, given its high prevalence in the Chinese population. In contrast, the replication study intentionally excluded PCV from the case cohort on the basis of ICG angiograms. Therefore, the inconsistent finding might be caused by potential sample heterogeneity between these two studies. In this respect, this association needed to be examined in a case series of clearly defined individuals with neovascular AMD and PCV. The aim of this study was to validate the previously reported association of the PEDF Met72Thr variant in a well characterized Japanese population with neovascular AMD and PCV.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 102 105 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 123 135 <span type="species:ncbi:9606">participants</span>
###xml 282 285 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
We genotyped the Met72Thr variant (rs1136287) in 116 patients with neovascular AMD, 140 patients with PCV, and 189 control participants in a Japanese population. Genotyping was performed using TaqMan technology. We tested for an association of this variant with neovascular AMD and PCV separately. We also evaluated population stratification in our study cohort.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 111 114 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
We found no statistically significant evidence for association between rs1136287 and either neovascular AMD or PCV under any genetic models (trend, genotypic, dominant, and recessive genetic models; p>0.05). Population structure analyses excluded stratification artifact in our study population.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 96 99 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 242 245 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
We report a lack of association between the PEDF Met72Thr variant and either neovascular AMD or PCV in a Japanese population. We conclude that the Met72Thr variant does not play a significant role in the risk of developing neovascular AMD or PCV.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 503 506 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Age-related macular degeneration (AMD), a leading cause of blindness among older individuals in developed countries [1], is a heterogeneous group of disorders with variable clinical findings [2]. It manifests at an early stage with large drusen and pigmentary abnormalities in the retinal pigment epithelium at the macula. With progression to an advanced stage, it presents with geographic atrophy (dry AMD) or exudative maculopathy (wet/neovascular AMD) as the sequela of choroidal neovascularization (CNV).
###end p 11
###begin p 12
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 671 672 671 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 846 847 846 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 945 946 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 1138 1140 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 1141 1143 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 126 129 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 349 352 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 567 570 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 681 684 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 765 773 <span type="species:ncbi:9606">patients</span>
Inner choroidal vascular networks ending in polypoidal lesions are the defining feature of polypoidal choroidal vasculopathy (PCV) [3-5], which is now clinically classified into a specific type of AMD [6]. Some clinical and pathological features such as demography [7], pathology [8-10], and manifestation [7] are common between neovascular AMD and PCV; however, important differences are also noted in clinical behavior [3], histopathology [11,12], and response to therapy [13,14]. These commonalities and differences have been a source of much debate as to whether PCV has a common etiology with neovascular AMD or a distinct phenotype reflecting a different etiology [8-12,15]. PCV has a particularly high incidence in Asian populations, accounting for 54.7% of patients with findings suggestive of neovascular AMD in the Japanese population [7] and 24.5% in the Chinese population [16], in contrast to only 8 to 13% in European populations [3]. The phenotypic spectrum of AMD is quite heterogeneous among different ethnicities. Dry AMD is more frequent in European populations than in Asians; the reverse is true for neovascular AMD [17-19].
###end p 12
###begin p 13
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 351 354 351 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 403 412 403 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 628 631 628 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 645 650 645 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 651 656 651 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 1015 1019 1015 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TLR3</italic>
###xml 1039 1041 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 1334 1336 1334 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 587 590 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 778 781 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 942 945 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 1171 1174 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
To date, many studies have reported various gene variants associated with AMD [20,21]. However, findings from most studies have been largely inconclusive because of a lack of consistent replication [20,21]. Thus far, variants in two genomic regions have been consistently reproducible across multiple ethnic groups, including the complement factor H (CFH) gene at chromosome 1q32 [22-26] and the ARMS2 (LOC387715)/HTRA1 locus at 10q26 [27-30]. These two loci are associated with all phenotypes of AMD, including early AMD, dry AMD, and neovascular AMD [25,27]. Genetic susceptibility to PCV is also strongly associated with the CFH gene and the ARMS2/HTRA1 locus [31,32], thus indicating that these two loci play a general role in the etiology of variable phenotypes of AMD and PCV. Besides these shared genetic associations, two phenotype-specific associations have been found. These associations are common variants in the elastin gene for PCV [33] and an allelic variant (Leu412Phe) in the toll-like receptor 3 (TLR3) gene for dry AMD [34]. From the genetic perspective, both general and phenotype-specific pathways may be implicated in the pathophysiology of AMD and PCV. Therefore, to avoid variable findings across studies, attention to disease classification is a key aspect of genetic studies on AMD, as suggested previously [35].
###end p 13
###begin p 14
###xml 12 14 12 14 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 643 647 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 691 695 691 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
Lin et al. [36] recently reported a previously unknown association between neovascular AMD and the coding Met72Thr (rs1136287) variant in the pigment epithelium-derived factor (PEDF) gene in a Taiwan Chinese population. The authors reported that the minor allele T of rs1136287 was significantly associated with increased disease risk, with an odds ratio (OR) of 3.9 under a recessive disease model [36]. At present, there is no evidence for functional relevance of the Met72Thr variant, nor has any biologic explanation been proposed for this association. Still, there are multiple lines of evidence for the importance of the protein product PEDF in the pathogenesis of AMD [37], and thus, PEDF is a reasonable candidate gene for the disease.
###end p 14
###begin p 15
###xml 15 17 15 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 1042 1046 1042 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TLR3</italic>
###xml 1093 1095 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 1127 1130 1127 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TLR</italic>
###xml 1152 1156 1152 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TLR3</italic>
###xml 1352 1356 1352 1356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TLR3</italic>
###xml 1407 1409 1407 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 1649 1653 1649 1653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 1979 1983 1979 1983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 491 494 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 597 600 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 744 747 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 758 770 <span type="species:ncbi:9606">participants</span>
###xml 1893 1896 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 2070 2073 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Mattes et al. [38] subsequently failed to replicate this association in a white European population with neovascular AMD. We noted an important difference in the sample ascertainment scheme between these two studies [36,38]. Lin et al. [36] applied consensus criteria for AMD classification derived from analysis of a white population and did not consider findings of indocyanine green (ICG) angiography for disease classification. ICG angiography is the only way to obtain a clear image of PCV lesions [3]. The work of Lin et al. suggests that their cohort might include a considerable amount of PCV, given its high prevalence in the Chinese population [16]. However, Mattes et al. [38] performed ICG angiography and excluded individuals with PCV from case participants. Since genetic susceptibility to distinct AMD phenotypes seems to be influenced by different genetic factors [33-35], genetic association studies on AMD can be confounded by underlying sample heterogeneity. An example of this situation can be seen in previous studies on TLR3 for its association with AMD. Edwards et al. [39] examined polymorphisms across TLR genes, including the TLR3 Leu412Phe variant, in a mixed sample of early AMD, dry AMD, and neovascular AMD. This analysis was not restricted to dry AMD, and the authors failed to detect a phenotype-specific association of TLR3 Leu412Phe with dry AMD. In contrast, Yang et al. [34] selectively studied subgroups of subjects with early AMD, dry AMD, and neovascular AMD and eventually found that the Leu412Phe variant specifically contributes to the risk of developing dry AMD. Similarly, the inconsistent finding of the PEDF Met72Thr variant could be due to potential sample heterogeneity between the studies by Lin et al. and Mattes et al. Therefore, this association needed to be examined in a case series of clearly defined individuals with neovascular AMD and PCV. The aim of this study was to validate the previously reported association of the PEDF Met72Thr variant in a well characterized Japanese population with neovascular AMD and PCV.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants
###end title 17
###begin p 18
###xml 329 336 329 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 1287 1289 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 218 230 <span type="species:ncbi:9606">participants</span>
###xml 253 265 <span type="species:ncbi:9606">participants</span>
###xml 313 325 <span type="species:ncbi:9606">participants</span>
###xml 621 624 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 791 794 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 798 801 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 803 811 <span type="species:ncbi:9606">Patients</span>
###xml 898 901 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1018 1030 <span type="species:ncbi:9606">participants</span>
###xml 1065 1077 <span type="species:ncbi:9606">participants</span>
This study was approved by the Institutional Review Board at Kobe University Graduate School of Medicine and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. All case and control participants enrolled in this study (more information about participants in Table 1) were Japanese individuals recruited from the Department of Ophthalmology at Kobe University Hospital in Kobe, Japan. This is largely the same sample set used in our previous studies in which phenotyping criteria were fully described [31-33,40]. In brief, all our neovascular AMD and PCV subjects underwent comprehensive ophthalmic examinations, including ICG angiography, and were defined as individuals with angiographically well delineated lesions of CNV or PCV. Patients with secondary choroidal neovascular diseases such as degenerative myopia, idiopathic CNV, ocular trauma, angioid streaks, and presumed ocular histoplasmosis were excluded from the recruitment. The control participants, who were not related to the case participants, were defined as individuals without macular degeneration and changes such as drusen or pigment abnormalities, and thus, were categorized as having the clinical age-related maculopathy staging system stage 1 [41].
###end p 18
###begin title 19
Characteristics of the study population
###end title 19
###begin p 20
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 64 67 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 85 97 <span type="species:ncbi:9606">participants</span>
###xml 300 303 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
A total of 116 patients with neovascular AMD, 140 patients with PCV, and 189 control participants were enrolled in the present study. The gender breakdown, mean age, and age range of each population are shown. Abbreviations: age-related macular degeneration (AMD); polypoidal choroidal vasculopathy (PCV); standard deviation (SD).
###end p 20
###begin title 21
Genotyping
###end title 21
###begin p 22
###xml 129 132 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
Genomic DNA was extracted from peripheral blood immediately after it was drawn. We genotyped the Met72Thr variant () using TaqMan(R) SNP Genotyping Assays (Assay ID: C___1841779_20; Applied Biosystems, Foster City, CA) on a StepOnePlustrade mark Real-Time PCR system (Applied Biosystems), in accordance with the manufacturer's instructions. For verification, a random 10% of samples were genotyped twice, yielding 100% concordance.
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 294 295 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 337 338 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 385 386 379 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 526 528 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 959 961 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 1127 1130 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 1320 1323 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Testing for association was performed using software packages  v3.02. Deviations from Hardy-Weinberg equilibrium (HWE) were evaluated using the exact test [42] implemented in . We performed association analyses using the Cochran-Armitage trend test [43] and genotypic (2 degrees of freedom, chi2 test), dominant (1 degree of freedom, chi2 test), and recessive (1 degree of freedom, chi2 test) genetic models. The max(T) permutation procedure implemented in  v1.00 was used with 10,000 iterations to obtain empirical p values [44]. To adjust for age and gender differences between case and control subjects, we conducted logistic regression analyses using JMP version 6.0.3 software (SAS Institute, Cary, NC), assuming a multiplicative codominant genetic model by fitting the number of minor allele carried as an ordinal covariate and age and gender as continuous and categorical covariates, respectively. Power calculations were performed using  version 1.2 [45]. We had full power to detect the OR reported in the original studies for rs1136287 (OR=3.90 under a recessive genetic model) at p<0.05 for both neovascular AMD and PCV. Assuming an additive genetic model, we had 80% power to detect an association of this variant with ORs >/=1.61 (or </=0.62) for the neovascular AMD sample and >/=1.56 (or </=0.63) for the PCV sample.
###end p 24
###begin p 25
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
Linkage disequilibrium (LD) structures across the PEDF gene were compared between Chinese and Japanese populations, using genotype data retrieved from the HapMap [46] CHB (Han Chinese in Beijing, China) and JPT (Japanese in Tokyo, Japan) data sets. These retrieved data were loaded into Haploview [47] to estimate LD parameters and identify haplotype blocks.
###end p 25
###begin p 26
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r50">50</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r51">51</xref>
###xml 441 442 441 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 991 992 991 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1123 1124 1123 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1176 1178 1176 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pr</italic>
###xml 1180 1181 1180 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1263 1265 1263 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
Hidden population stratification in genetic association studies can generate a spurious positive or negative association [48]. To prevent potential stratification in our study cohort, we evaluated population stratification using STRUCTURE software [49], as described in previous studies [40,50,51]. The following 38 single nucleotide polymorphisms (SNPs), which were randomly distributed along the genome and are not in LD with each other (r2<0.04), were used for stratification analysis:  (1p13.2),  (1p21.3),  (1p36.12),  (1q32.1),  (2p23.1),  (2p24.1),  (2q35),  (3p26.2),  (3q25.32),  (4q13.3),  (5p15.1),  (6p11.2),  (7p22.1),  (7q22.1),  (8p12),  (9p21.3),  (9p24.3),  (9q33.1),  (10q11.22),  (10q24.2),  (11p15.5),  (11q24.3),  (12p13.2),  (12p13.33),  (12q13.3),  (13q12.11),  (14q13.2),  (14q32.13),  (15q22.31),  (16q24.3),  (17p13.2),  (17q23.1),  (18q11.2),  (19p13.2),  (19p13.3),  (20p11.21),  (21q21.1), and  (22q13.1). The log likelihood of each analysis at a varying number K (the number of populations) was computed from three independent runs (20,000 burn-in and 30,000 iterations). The best estimate of K was defined by calculating posterior probabilities Pr (K=1, 2, 3, 4, or 5) based on the log likelihood, as described by Pritchard et al. [52].
###end p 26
###begin title 27
Results
###end title 27
###begin p 28
###xml 125 132 125 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 64 67 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 85 97 <span type="species:ncbi:9606">participants</span>
###xml 296 308 <span type="species:ncbi:9606">participants</span>
A total of 116 patients with neovascular AMD, 140 patients with PCV, and 189 control participants participated in the study. Table 1 shows the demographic details of the study population. The PEDF Met72Thr () variant showed no significant deviation from Hardy-Weinberg equilibrium in the control participants (p=0.66).
###end p 28
###begin p 29
###xml 79 86 79 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 220 227 220 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 190 193 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 405 408 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Details of allele and genotype counts and summary statistics for  are shown in Table 2. We found no statistically significant evidence for association between  and either neovascular AMD or PCV under any genetic models (Table 2). Adjusting for age and gender by logistic regression analyses did not affect the conclusion (age- and sex-adjusted p=0.59 for neovascular AMD; age- and sex-adjusted p=0.33 for PCV, under a multiplicative codominant model).
###end p 29
###begin title 30
Allele and genotype distributions of rs1136287 and the results of association tests
###end title 30
###begin p 31
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 712 715 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
The trend p values were obtained by the Cochran-Armitage trend test. Genotypic p values were generated by chi-square tests on 2x3 contingency tables. Tests for the dominant and recessive models were set up as 2x2 contingency table chi-square tests. The dominant model compared a combination of C/T+T/T genotypes to the homozygous C/C. The recessive model compared a combination of C/C+C/T to the homozygous T/T. Empirical p values were generated by 10,000 permutation tests, using the max(T) permutation procedure implemented in PLINK [44]. Asterisk (*) indicates OR trend test. Abbreviations: odds ratio (OR); confidence interval (CI); age-related macular degeneration (AMD); polypoidal choroidal vasculopathy (PCV).
###end p 31
###begin p 32
###xml 458 462 458 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 750 754 750 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 761 769 761 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
We also explored the possibility that failure to replicate the previously reported association could arise due to differences in LD structure between Chinese and Japanese populations-i.e., if the Met72Thr variant is only a proxy for some other true causative variant, the inconsistency may be due to a difference in LD for a pair of the Met72Thr and causal variants between Chinese and Japanese populations. To this end, we compared LD structures across the PEDF gene between Chinese and Japanese populations, using genotype data retrieved from the HapMap [46] CHB and JPT data set. This analysis revealed that the HapMap Chinese (CHB) and Japanese (JPT) populations are highly similar with regard to LD pattern and structure of LD blocks across the PEDF gene (Figure 1).
###end p 32
###begin p 33
###xml 197 198 197 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 235 236 235 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
###xml 499 500 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Linkage disequilibrium structure across the pigment epithelium-derived factor gene in Chinese and Japanese populations. Genotype data were retrieved from HapMap CHB (Han Chinese in Beijing, China; A) and JPT (Japanese in Tokyo, Japan; B) data sets, and linkage disequilibrium (LD) patterns were assessed using Haploview software [47]. Haplotype blocks were determined using the "four-gamete rule" option in this software. Each box provides estimated statistics of the coefficient of determination (r2), with darker shades representing stronger LD.
###end p 33
###begin p 34
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
Next, we examined SNPs within PEDF in an available data set, the  database. This database provides results of genome-wide association analysis for 395 individuals with AMD and 198 controls from the National Eye Institute Age-Related Eye Disease Study (AREDS). This genome-wide association study investigated seven PEDF SNPs, including the SNP  (Met72Thr) tested here and six other SNPs (, , , , , and ). None of these seven SNPs showed significant association with AMD in this analysis (p>0.05).
###end p 34
###begin p 35
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
Hidden population stratification between case and control subjects can be a confounding factor yielding false-positive or false-negative findings [48]. Population stratification was examined by STRUCTURE [49], using 38 unlinked genome-wide SNPs. We found no evidence of stratification in our study cohort, using the formula;
###end p 35
###begin p 36
thus indicating that our results did not arise from population stratification.
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 200 203 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 331 334 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 525 528 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
To validate the recently reported association between the PEDF Met72Thr variant and wet AMD in a Taiwan Chinese population [36], we analyzed this variant in Japanese subjects with neovascular AMD and PCV separately, given the possibility that a case population of the original report might be a mixed sample of neovascular AMD and PCV. Despite sufficient power to replicate the originally reported association, we found no statistically significant evidence for association between this variant and either neovascular AMD or PCV.
###end p 38
###begin p 39
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r54">54</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r54">54</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r55">55</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r56">56</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r57">57</xref>
###xml 435 439 435 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r58">58</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r59">59</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r60">60</xref>
###xml 751 755 751 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 347 350 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 488 491 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 538 541 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 547 553 <span type="species:ncbi:10090">murine</span>
###xml 671 674 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
PEDF is mainly a secreted 50 kDa glycoprotein that is found in various ocular tissues including retinal pigment epithelium and choroid [53,54]. PEDF potently inhibits angiogenesis and plays a pivotal role in maintaining vascular quiescence in the eye [54,55]. Specifically, PEDF has been repeatedly implicated in the pathology of neovascular AMD: CNV is associated with decreased levels of PEDF in an eye with neovascular AMD [56,57], PEDF gene transfer in the eye inhibits laser-induced CNV growth and promotes regression of established CNV in a murine model [58,59], and adenoviral vector-mediated intravitreal gene transfer of PEDF seems to help prevent the growth of CNV in patients with neovascular AMD [60]. Thus, from a functional perspective, PEDF appeared to be a reasonable candidate for genetic susceptibility to neovascular AMD.
###end p 39
###begin p 40
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r61">61</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r62">62</xref>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r61">61</xref>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r62">62</xref>
###xml 1090 1092 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 1229 1233 1229 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 1325 1327 1325 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 1451 1455 1451 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 1462 1470 1462 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 1493 1495 1493 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 1553 1555 1553 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 344 347 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 1762 1767 <span type="species:ncbi:9606">human</span>
Disease heterogeneity can result in false-positive reporting or can obscure the existence of true associations. Population stratification can also generate inconsistent findings across studies, thus yielding false-positive or false-negative association. To address these concerns, we performed association analysis for both neovascular AMD and PCV because of the unclear definition of the disease phenotype included in the original study [36]. We also examined population stratification in our study cohort and confirmed the lack of stratification. Many other reasons for irreproducibility of initial positive findings have been cited, with failure to exclude chance being considered the most likely explanation for difficulty in replication [61,62]. To protect against a range of confounding factors and to provide greater support for a claim of association, initial positive studies should preferably include multiple replication samples [61,62]. However, Lin et al. did not validate their finding in a second sample, nor did they evaluate potential stratification in their study cohort [36]. Finally, our inability to replicate the previously reported association may result from differences in the structure of LD across the PEDF gene region between Chinese and Japanese populations. However, examination of HapMap data [46] revealed that the HapMap Chinese and Japanese populations are similar in LD pattern and structure of LD blocks across the PEDF gene (Figure 1). Mattes et al. also [38] failed to replicate the original finding of Lin et al. [36]. Additional support of our negative findings comes from the genome-wide association study on the . Our experience highlights the importance of replication efforts in genetic association studies of complex human diseases.
###end p 40
###begin p 41
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEDF</italic>
###xml 111 114 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 257 260 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
In conclusion, we report a lack of association between the PEDF Met72Thr variant and either neovascular AMD or PCV in a Japanese population. We conclude that the Met72Thr variant does not play a significant role in the risk of developing neovascular AMD or PCV.
###end p 41
###begin title 42
Acknowledgments
###end title 42
###begin p 43
This study was supported by a grant-in-aid (C) 17591836 from the Ministry of Education, Science, and Culture, Tokyo, Japan. None of the authors have any financial or conflicting interests to disclose.
###end p 43
###begin title 44
References
###end title 44
###begin article-title 45
Prevalence of age-related macular degeneration in the United States.
###end article-title 45
###begin article-title 46
Age-related macular degeneration.
###end article-title 46
###begin article-title 47
Polypoidal choroidal vasculopathy.
###end article-title 47
###begin article-title 48
###xml 46 50 <span type="species:ncbi:32629?0.2">IPCV</span>
Idiopathic polypoidal choroidal vasculopathy (IPCV).
###end article-title 48
###begin article-title 49
Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration.
###end article-title 49
###begin article-title 50
Working Group for Establishing Diagnostic Criteria for Age-Related Macular Degeneration. Classification and diagnostic criteria of age-related macular degeneration.
###end article-title 50
###begin article-title 51
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of exudative age-related macular degeneration in Japanese patients.
###end article-title 51
###begin article-title 52
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration.
###end article-title 52
###begin article-title 53
Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation.
###end article-title 53
###begin article-title 54
Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
###end article-title 54
###begin article-title 55
Correlation between indocyanine green angiographic findings and histopathology of polypoidal choroidal vasculopathy.
###end article-title 55
###begin article-title 56
Clinicopathologic findings in polypoidal choroidal vasculopathy.
###end article-title 56
###begin article-title 57
Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy.
###end article-title 57
###begin article-title 58
Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.
###end article-title 58
###begin article-title 59
The origins of polypoidal choroidal vasculopathy.
###end article-title 59
###begin article-title 60
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Subtype lesions of neovascular age-related macular degeneration in Chinese patients.
###end article-title 60
###begin article-title 61
Prevalence of age-related maculopathy. The Beaver Dam Eye Study.
###end article-title 61
###begin article-title 62
Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study.
###end article-title 62
###begin article-title 63
Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study.
###end article-title 63
###begin article-title 64
The genetics of age-related macular degeneration: a review of progress to date.
###end article-title 64
###begin article-title 65
An update on the genetics of age-related macular degeneration.
###end article-title 65
###begin article-title 66
Complement factor H polymorphism and age-related macular degeneration.
###end article-title 66
###begin article-title 67
Complement factor H variant increases the risk of age-related macular degeneration.
###end article-title 67
###begin article-title 68
Complement factor H polymorphism in age-related macular degeneration.
###end article-title 68
###begin article-title 69
CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD.
###end article-title 69
###begin article-title 70
Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration.
###end article-title 70
###begin article-title 71
HTRA1 variant confers similar risks to geographic atrophy and neovascular age-related macular degeneration.
###end article-title 71
###begin article-title 72
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA.
###end article-title 72
###begin article-title 73
HTRA1 promoter polymorphism in wet age-related macular degeneration.
###end article-title 73
###begin article-title 74
A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration.
###end article-title 74
###begin article-title 75
LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population.
###end article-title 75
###begin article-title 76
Coding variant I62V in the complement factor H gene is strongly associated with polypoidal choroidal vasculopathy.
###end article-title 76
###begin article-title 77
Elastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
###end article-title 77
###begin article-title 78
Toll-like receptor 3 and geographic atrophy in age-related macular degeneration.
###end article-title 78
###begin article-title 79
Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits.
###end article-title 79
###begin article-title 80
Pigment epithelium-derived factor gene Met72Thr polymorphism is associated with increased risk of wet age-related macular degeneration.
###end article-title 80
###begin article-title 81
Current concepts in the pathogenesis of age-related macular degeneration.
###end article-title 81
###begin article-title 82
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Analysis of three pigment epithelium-derived factor gene polymorphisms in patients with exudative age-related macular degeneration.
###end article-title 82
###begin article-title 83
Toll-like receptor polymorphisms and age-related macular degeneration.
###end article-title 83
###begin article-title 84
Coding variant I62V in the complement factor H gene is strongly associated with polypoidal choroidal vasculopathy.
###end article-title 84
###begin article-title 85
Evaluation of the clinical age-related maculopathy staging system.
###end article-title 85
###begin article-title 86
A note on exact tests of Hardy-Weinberg equilibrium.
###end article-title 86
###begin article-title 87
A tutorial on statistical methods for population association studies.
###end article-title 87
###begin article-title 88
PLINK: a tool set for whole-genome association and population-based linkage analyses.
###end article-title 88
###begin article-title 89
Sample size requirements for matched case-control studies of gene-environment interaction.
###end article-title 89
###begin article-title 90
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 90
###begin article-title 91
###xml 15 20 <span type="species:ncbi:9606">human</span>
The effects of human population structure on large genetic association studies.
###end article-title 91
###begin article-title 92
Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies.
###end article-title 92
###begin article-title 93
A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction.
###end article-title 93
###begin article-title 94
Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia.
###end article-title 94
###begin article-title 95
Inference of population structure using multilocus genotype data.
###end article-title 95
###begin article-title 96
###xml 81 86 <span type="species:ncbi:9606">human</span>
Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues.
###end article-title 96
###begin article-title 97
PEDF: Raising both hopes and questions in controlling angiogenesis.
###end article-title 97
###begin article-title 98
Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.
###end article-title 98
###begin article-title 99
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration.
###end article-title 99
###begin article-title 100
Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degeneration.
###end article-title 100
###begin article-title 101
AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization.
###end article-title 101
###begin article-title 102
Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor.
###end article-title 102
###begin article-title 103
Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.
###end article-title 103
###begin article-title 104
Problems of reporting genetic associations with complex outcomes.
###end article-title 104
###begin article-title 105
Replicating genotype-phenotype associations.
###end article-title 105

